
The Honorable Charles Schumer
Majority Leader
US Senate
S-221 Capitol Building
Washington, DC 20510

The Honorable Mitch McConnell
Minority Leader
US Senate
S-230 Capitol Building
Washington, DC 20510

The Honorable Mike Johnson
Speaker of the House
US House of Representatives
H-232 Capitol Building
Washington, DC 20515

The Honorable Hakeem Jeffries
Minority Leader
US House of Representatives
H-204 Capitol Building
Washington, DC 20515

Re: The Urgent Need to Reauthorize PAHPA

Dear Leaders Schumer and McConnell, Speaker Johnson, and Leader Jeffries,

On behalf of the undersigned organizations, we write to express our strong desire to see the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorized before the end of the calendar year in the same bipartisan fashion it has been supported since the original authorization 17 years ago.

As you know, PAHPA underpins Department of Health and Human Services (HHS) agencies, programs, and funding authorizations for addressing national health security threats. PAHPA created the HHS Assistant Secretary for Preparedness and Response (now the Administration for Strategic Preparedness and Response) and the Biomedical Advanced Research and Development Authority (BARDA) and provides important congressional oversight and direction to federal programs related to early warning, prevention, preparedness, and response.

This overall framework expired on September 30, 2023, requiring stopgap, temporary extensions in the continuing resolution, which expires on November 17. We encourage Congress to include a comprehensive five-year PAHPA reauthorization in the next moving legislative vehicle.

The last three PAHPA bills all shared major recurring themes: they all adjusted to the changing threat landscape, focused on challenges identified since the prior bill, and considerably strengthened our nation's health security with each reauthorization.

Our nation's changing health security threat landscape and the federal government's responsibility to protect the American people demand that we work together now to find a strong bipartisan path forward to reauthorize this critical legislation. Whether the next health security threat is naturally occurring, the result of an accident, or intentionally caused, our country must be in a better position to prevent, prepare for, and respond to such incidents.

Failing to reauthorize PAHPA would have serious effects on our country's economic wellbeing, national security, and health security given the rapidly changing threat landscape.

We are hopeful that PAHPA will remain a strong bipartisan legislative framework, as it has always been. We stand ready to assist you in whatever ways we can to help get this important law reauthorized this year.

Sincerely (in alphabetical order),

1Day Sooner

Acadian Ambulance Service, Inc.

Adaptive Phage Therapeutics

Aequor Inc.

Alliance for Biosecurity

American Ambulance Association America's

Essential Hospitals

American College of Emergency Physicians

American College of Surgeons

American Hospital Association

American Lung Association

American Pharmacies

American Public Health Association

American Society for Microbiology

Arizona Bioindustry Association, Inc.

(AZBio)

**Association for Professionals in Infection
Control and Epidemiology**

**Association of Maternal & Child Health
Programs**

**Association of State and Territorial Health
Officials**

Asthma and Allergy Foundation of America

AstraZeneca Pharmaceuticals

ATCC (American Type Culture Collection)

Atea Pharmaceuticals, Inc.

Bavarian Nordic

Big Cities Health Coalition

BioCT

BioForward Wisconsin

BioKansas

BioNJ

Biotechnology Innovation Organization (BIO)

Bugworks

Cencora

Colorado BioScience Association

**Council of State and Territorial
Epidemiologists**

**Council of State Bioscience Associations
(CSBA)**

CSL Seqirus

**Emergency Department Practice
Management Association**

Emergent BioSolutions

Federation of American Scientists

FluGen Inc.

Georgia Bio

Gerontological Society of America

Ginkgo Bioworks

Global Health Investment Corporation Global

Health Technologies Coalition Gryphon

Scientific

GSK

**Health Industry Distributors Association
(HIDA)**

Healthcare Distribution Alliance

Healthcare Leadership Council	Novavax
Healthcare Ready	Ochsner Health
Helix	Ohio Life Sciences Association Oklahoma
HIMSS (Healthcare Information and Management Systems Society)	Bioscience Association
HIV Medicine Association	PDS Biotechnology
IAVI (International AIDS Vaccine Initiative)	PharmaJet Inc.
Illinois Biotechnology Innovation Organization	Premier Inc.
Infectious Diseases Society of America	Public Health Accreditation Board
INOVIO Pharmaceuticals	Research!America
Institute for Progress	SAB Biotherapeutics, Inc.
Johns Hopkins Center for Health Security	Sanofi
Life Sciences PA	SecureBio
Locus Biosciences	Shionogi Inc.
Mallinckrodt	SIGA Technologies, Inc.
Marked By Covid	Society for Public Health Education
MassBio	Soligenix, Inc.
McKesson	Technologies for Pandemic Defense Texas
Medical Alley	Healthcare & Bioscience Institute Tonix
Medical Countermeasures Coalition	Pharmaceuticals
Missouri Biotechnology Association (MOBIO)	Trinity Health
National Association of County and City Health Officials	TrippBio, Inc.
National Immigration Law Center	Trust for America's Health
New Mexico Biotechnology & Biomedical Association (NMBio)	United States Pharmacopeia (USP)
New Orleans BioInnovation Center	University of Hawaii
NewYorkBIO	University of Maryland School of Medicine
NightHawk Biosciences	Valneva USA
	Vaxxas Inc
	Virginia Biotechnology Association

cc:

Chair Bernie Sanders
Health, Education, Labor & Pensions Committee
US Senate

Ranking Member Bill Cassidy
Health, Education, Labor & Pensions Committee
US Senate

Chair Cathy McMorris Rodgers
Energy & Commerce Committee
US House of Representatives

Ranking Member Frank Pallone
Energy & Commerce Committee
US House of Representatives